OBJECTIVES: Acromegaly is a rare disorder characterized by over-secretion of GH, most often because of a pituitary adenoma. The disease is associated with disturbances in lipoprotein metabolism and an increased cardiovascular mortality. The aim of the present study was to investigate whether treatment of acromegaly results in changes in serum concentrations of lipids and apolipoproteins, including lipoprotein(a) (Lp(a)). DESIGN: Fourteen patients with clinical features of acromegaly and increased GH secretion were studied 1-10 months before and 6-15 months after transsphenoidal adenomectomy in an open study. PATIENTS: Three patients had diabetes mellitus before surgery and two of these patients had normalized serum glucose levels post-operatively. Mean and baseline plasma GH levels were determined from 24-hour GH profiles. Serum samples were taken in the morning after an overnight fast. All patients were normocholesterolaemic, and four patients were hypertriglyceridaemic before treatment. RESULTS: Mean plasma GH levels decreased from 34.5 +/- 7.4 to 2.1 +/- 0.4 mU/l (mean +/- SEM). Serum IGF-I, insulin and free T3 levels decreased and serum SHBG concentrations increased post-operatively. There was no effect of treatment on serum cholesterol concentrations, but serum triglyceride concentrations decreased. Serum apolipoprotein (apo) B and apoE levels were unaffected by treatment. Serum apoA-I levels increased and Lp(a) levels decreased post-operatively. CONCLUSIONS: Successful treatment of acromegaly, resulting in normal mean GH values (< 5 mU/l) and/or normal responsiveness to TRH, have beneficial effects on serum lipoproteins with increased serum apoA-I levels and decreased serum levels of triglycerides and Lp(a). These effects seem to be independent of improvement in glucose tolerance, since patients with diabetes mellitus before surgery and normal fasting blood glucose levels post-operatively had similar lipoprotein responses to treatment as those with normal fasting blood glucose levels before surgery.
OBJECTIVES:Acromegaly is a rare disorder characterized by over-secretion of GH, most often because of a pituitary adenoma. The disease is associated with disturbances in lipoprotein metabolism and an increased cardiovascular mortality. The aim of the present study was to investigate whether treatment of acromegaly results in changes in serum concentrations of lipids and apolipoproteins, including lipoprotein(a) (Lp(a)). DESIGN: Fourteen patients with clinical features of acromegaly and increased GH secretion were studied 1-10 months before and 6-15 months after transsphenoidal adenomectomy in an open study. PATIENTS: Three patients had diabetes mellitus before surgery and two of these patients had normalized serum glucose levels post-operatively. Mean and baseline plasma GH levels were determined from 24-hour GH profiles. Serum samples were taken in the morning after an overnight fast. All patients were normocholesterolaemic, and four patients were hypertriglyceridaemic before treatment. RESULTS: Mean plasma GH levels decreased from 34.5 +/- 7.4 to 2.1 +/- 0.4 mU/l (mean +/- SEM). Serum IGF-I, insulin and free T3 levels decreased and serum SHBG concentrations increased post-operatively. There was no effect of treatment on serum cholesterol concentrations, but serum triglyceride concentrations decreased. Serum apolipoprotein (apo) B and apoE levels were unaffected by treatment. Serum apoA-I levels increased and Lp(a) levels decreased post-operatively. CONCLUSIONS: Successful treatment of acromegaly, resulting in normal mean GH values (< 5 mU/l) and/or normal responsiveness to TRH, have beneficial effects on serum lipoproteins with increased serum apoA-I levels and decreased serum levels of triglycerides and Lp(a). These effects seem to be independent of improvement in glucose tolerance, since patients with diabetes mellitus before surgery and normal fasting blood glucose levels post-operatively had similar lipoprotein responses to treatment as those with normal fasting blood glucose levels before surgery.
Authors: E Lin; T L Wexler; L Nachtigall; N Tritos; B Swearingen; L Hemphill; J Loeffler; B M K Biller; A Klibanski; K K Miller Journal: Clin Endocrinol (Oxf) Date: 2012-09 Impact factor: 3.478
Authors: M C De Martino; R S Auriemma; G Brevetti; G Vitale; V Schiano; M Galdiero; L Grasso; G Lombardi; A Colao; R Pivonello Journal: J Endocrinol Invest Date: 2010-07-01 Impact factor: 4.256
Authors: Carlos Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Celina Crisman; Irene M Conwell; Jane Kostadinov; Eliza B Geer; Kalmon D Post; Pamela U Freda Journal: J Clin Endocrinol Metab Date: 2014-08-19 Impact factor: 5.958
Authors: A Giustina; F F Casanueva; F Cavagnini; P Chanson; D Clemmons; L A Frohman; R Gaillard; K Ho; P Jaquet; D L Kleinberg; S W J Lamberts; G Lombardi; M Sheppard; C J Strasburger; M L Vance; J A H Wass; S Melmed Journal: J Endocrinol Invest Date: 2003-12 Impact factor: 4.256
Authors: Alin Abreu; Alejandro Pinzón Tovar; Rafael Castellanos; Alex Valenzuela; Claudia Milena Gómez Giraldo; Alejandro Castellanos Pinedo; Doly Pantoja Guerrero; Carlos Alfonso Builes Barrera; Humberto Ignacio Franco; Antônio Ribeiro-Oliveira; Lucio Vilar; Raquel S Jallad; Felipe Gaia Duarte; Mônica Gadelha; Cesar Luiz Boguszewski; Julio Abucham; Luciana A Naves; Nina Rosa C Musolino; Maria Estela Justamante de Faria; Ciliana Rossato; Marcello D Bronstein Journal: Pituitary Date: 2016-08 Impact factor: 4.107